Brind.

Analyst initiated coverage of Relay Therapeutics and mentioned a promising late-stage breast cancer trial at Canino.

1 report, 1 independent Updated Sep 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Analyst initiated coverage of Relay Therapeutics and mentioned a promising late-stage breast cancer trial at Canino.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Motley FoolWhy Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week An analyst initiated coverage of the biotech. Not only does he consider it a buy, he's also designated it as one of his firm's top pi